Notes
human epidermal growth factor receptor 2
Reference
NICE. NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company. Internet Document : 15 Feb 2019. Available from: URL: https://www.nice.org.uk/news/article/nice-draft-guidance-recommends-pertuzumab-for-new-breast-cancer-indication-after-improved-price-offer-from-company
Rights and permissions
About this article
Cite this article
NICE recommends pertuzumab for early HER2-positive breast cancer. PharmacoEcon Outcomes News 822, 24 (2019). https://doi.org/10.1007/s40274-019-5676-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5676-1